CALIDI BIOTHERAPEUTICS INC.

NYSE: CLDI (Calidi Biotherapeutics, Inc.)

最近更新时间: 04 Aug, 2:59AM

0.590

-0.01 (-0.92%)

前收盘价格 0.596
收盘价格 0.579
成交量 1,810,808
平均成交量 (3个月) 17,329,720
市值 20,377,510
股市价格/股市净资产 (P/B) 3.39
52周波幅
0.203 (-65%) — 3.89 (558%)
稀释每股收益 (EPS TTM) -1.12
总债务/股东权益 (D/E MRQ) 64.46%
流动比率 (MRQ) 2.12
营业现金流 (OCF TTM) -22.99 M
杠杆自由现金流 (LFCF TTM) -15.51 M
资产报酬率 (ROA TTM) -111.74%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 看跌
Biotechnology (全球的) 混合的 看跌
股票 Calidi Biotherapeutics, Inc. - -

AIStockmoo 评分

0.2
分析师共识 0.0
内部交易活动 3.0
价格波动 0.5
技术平均移动指标 0.0
技术振荡指标 -2.5
平均 0.20

相关股票

股票 市值 DY P/E(TTM) P/B
CLDI 20 M - - 3.39
LCTX 274 M - - 5.90
CYBN 167 M - - 1.65
PLX 116 M - 29.20 2.59
ANRO 72 M - - 0.810
SER 53 M - 1.58 29.88

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.

部门 Healthcare
行业 Biotechnology
内部持股比例 5.43%
机构持股比例 15.88%

所有权

姓名 日期 持有股份
Belpointe Asset Management Llc 30 Jun 2025 249,833
Cpr Investments Inc. 30 Jun 2025 101,000
Red Wave Investments Llc 31 Mar 2025 80,828
Rs Crum Inc. 31 Mar 2025 55,313
Drive Wealth Management, Llc 31 Mar 2025 55,000
Delta Investment Management, Llc 31 Mar 2025 21,023

该时间范围内无数据。

名称 平均购买 ($) 平均卖出 ($) 总净额 总净值 ($)
JACKSON ANDREW C. 1.70 - 2,500 4,250
LEFTWICH SCOTT 1.70 - 125,000 212,500
POMA ERIC E 1.70 - 25,000 42,500
SCHOENECK JAMES A 1.70 - 75,000 127,500
累积净数量 227,500
累积净值 ($) 386,750
累积平均购买 ($) 1.70
累积平均卖出 ($) -
名称 持有人 日期 类型 数量 价格 价值 ($)
LEFTWICH SCOTT 董事 21 Aug 2025 买 (+) 125,000 1.70 212,500
SCHOENECK JAMES A 董事 21 Aug 2025 买 (+) 75,000 1.70 127,500
JACKSON ANDREW C. 职员 21 Aug 2025 买 (+) 2,500 1.70 4,250
POMA ERIC E 职员 21 Aug 2025 买 (+) 25,000 1.70 42,500
日期 类型 细节
21 Aug 2025 公告 Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
20 Aug 2025 公告 Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering
08 Aug 2025 公告 Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights
01 Aug 2025 公告 Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
29 Jul 2025 公告 Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma
25 Jul 2025 公告 Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025
22 Jul 2025 公告 Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on July 24
10 Jul 2025 公告 Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment
09 Jul 2025 公告 Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds
08 Jul 2025 公告 Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment
27 Jun 2025 公告 Calidi Biotherapeutics Announces Shareholder Letter from CEO
02 Jun 2025 公告 Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票